ライフサイエンスコーパス: Parkinson's disease

1 netic Resonance Imaging in ten patients with Parkinson's disease.

2 neurons is a promising approach to treating Parkinson's disease.

3 in the cytoplasm of degenerating neurons in Parkinson's disease.

4 k between synaptic endocytic dysfunction and Parkinson's disease.

5 hypotheses for dopaminergic neuron death in Parkinson's disease.

6 as observed in age-related diseases such as Parkinson's disease.

7 gical diseases, including drug addiction and Parkinson's disease.

8 international longitudinal study of de novo Parkinson's disease.

9 d in mitochondrial homeostasis and linked to Parkinson's disease.

10 e diseases including Alzheimer's disease and Parkinson's disease.

11 / hyperactivity disorder, schizophrenia, and Parkinson's disease.

12 2AR-selective compounds for the treatment of Parkinson's disease.

13 nitive health or impairment in patients with Parkinson's disease.

14 of glioblastoma, traumatic brain injury, and Parkinson's disease.

15 e diseases including Alzheimer's disease and Parkinson's disease.

16 ein, a protein forming amyloid aggregates in Parkinson's disease.

17 fy novel predictors for motor progression in Parkinson's disease.

18 ctional protein in a patient with late onset Parkinson's disease.

19 models in the design of treatment trials in Parkinson's disease.

20 er disease, are also potent risk factors for Parkinson's disease.

21 vicious cycle scenario faced by microglia in Parkinson's disease.

22 tility observed in patients with early-stage Parkinson's disease.

23 oprotective effects in preclinical models of Parkinson's disease.

24 the brain in patients with Huntington's and Parkinson's disease.

25 neurodegenerative disorder associated to the Parkinson's disease.

26 e disease phenotype in a C. elegans model of Parkinson's disease.

27 ceptor that is a target for the treatment of Parkinson's disease.

28 tibility, and the underlying neurobiology of Parkinson's disease.

29 gic innervation preceding the motor onset of Parkinson's disease.

30 t DOPA decarboxylase (DDC), a key protein in Parkinson's disease.

31 GF-beta signaling as a potential therapy for Parkinson's disease.

32 y increased risk for melanoma in people with Parkinson's disease.

33 rease in neurodegenerative disorders such as Parkinson's disease.

34 represent the most prevalent risk factor for Parkinson's disease.

35 brain communication, such as Alzheimer's and Parkinson's diseases.

36 generative disorders such as Alzheimer's and Parkinson's diseases.

37 erative disorders, including Alzheimer's and Parkinson's diseases.

38 cantly reduced in Alzheimer's, Huntington's, Parkinson's diseases.

39 ocerebrosidase receptor, impacts Gaucher and Parkinson's diseases.

40 orders including stroke, and Alzheimer's and Parkinson's diseases.

41 In Parkinson's disease, a disease-specific physiomarker was

42 he time of clinical diagnosis, patients with Parkinson's disease already have a wide range of motor a

43 everal brain disorders, including addiction, Parkinson's disease, Alzheimer's disease and schizophren

44 16 rest tremor recordings in tremor-dominant Parkinson's disease and 20 postural tremor recordings in

45 s in free water in 103 de novo patients with Parkinson's disease and 49 controls; (ii) 2- and 4-year

46 insights into other behavioural symptoms in Parkinson's disease and addictions in the general popula

47 findings with those in people with sporadic Parkinson's disease and age-matched healthy controls.

48 13-35 Hz) is commonly found in patients with Parkinson's disease and can be suppressed by dopaminergi

49 nuclein family has long been associated with Parkinson's disease and dementia.

50 ent cohort comprising a further 55 tremulous Parkinson's disease and essential tremor recordings.

51 Parkinson's disease and experimentally induced hemiparki

52 ar and clinical variables from patients with Parkinson's disease and healthy controls to construct an

53 apeutic interventions to treat patients with Parkinson's disease and impulse control disorders have s

54 In patients with Parkinson's disease and impulse control disorders, impai

55 misfolding and aggregation is a hallmark in Parkinson's disease and in several other neurodegenerati

56 are similar in LRRK2 mutation carriers with Parkinson's disease and individuals with sporadic Parkin

57 ion in LRRK2 mutation carriers with manifest Parkinson's disease and individuals with sporadic Parkin

58 rhabditis elegans) and the major symptoms of Parkinson's disease and primary progressive freezing gai

59 ew insight into mitochondrial pathologies in Parkinson's disease and provide new prospects for target

60 ion and neurotoxicity to the pathogenesis of Parkinson's disease and related alpha-synucleinopathies.

61 ld be a means of therapeutic intervention in Parkinson's disease and related conditions.

62 n have been linked to neuronal impairment in Parkinson's disease and related neurodegenerative disord

63 ent of PARK2, a gene intensively reported in Parkinson's disease and schizophrenia research.

64 been reported to be associated with autism, Parkinson's disease and schizophrenia, respectively.

65 icates that the CNR2 gene is associated with Parkinson's disease and substance use disorders.

66 associated with a probable decreased risk of Parkinson's disease and type-2 diabetes and an increased

67 e pathways of Alzheimer's, Huntington's, and Parkinson's diseases and has been identified as a potent

68 incident cases of dementia, 31 577 cases of Parkinson's disease, and 9247 cases of multiple sclerosi

69 mutation carriers, individuals with sporadic Parkinson's disease, and age-matched healthy controls se

70 st Parkinson's disease, people with sporadic Parkinson's disease, and age-matched healthy controls, a

71 ilarities between dementia with Lewy bodies, Parkinson's disease, and Alzheimer's disease.

72 substantia nigra as a progression marker in Parkinson's disease, and describe the pattern of progres

73 ents a major new avenue for investigation in Parkinson's disease, and effects on everyday symptoms sh

74 rative diseases such as Alzheimer's disease, Parkinson's disease, and Huntington's disease.

75 er's disease, amyotrophic lateral sclerosis, Parkinson's disease, and Huntington's disease.

76 , epilepsy, autism, Alzheimer's disease, and Parkinson's disease, and is considered a potential targe

77 phaS) is the primary protein associated with Parkinson's disease, and it undergoes aggregation from i

78 Incident diagnoses of dementia, Parkinson's disease, and multiple sclerosis were ascerta

79 relationship with the incidence of dementia, Parkinson's disease, and multiple sclerosis.

80 Dementia with Lewy bodies, Parkinson's disease, and Multiple System Atrophy are age

81 ation carriers, 13 individuals with sporadic Parkinson's disease, and nine healthy controls.

82 acular degeneration, traumatic brain injury, Parkinson's disease, and other neurodegenerations.

83 ression, schizophrenia, Alzheimer's disease, Parkinson's disease, and pain, provides convincing evide

84 mpared with controls, individuals with LRRK2 Parkinson's disease, and people with sporadic Parkinson'

85 models for amyotrophic lateral sclerosis and Parkinson's disease, and show a partial rescue of the Pa

86 which is vulnerable to neurodegeneration in Parkinson's disease, and the calbindin-positive dorsal t

87 er's disease, amyotrophic lateral sclerosis, Parkinson's disease, and the prototypic neuroinflammator

88 nson's disease and individuals with sporadic Parkinson's disease, and whether LRRK2 mutation carriers

89 ncers; cardiovascular disease and mortality; Parkinson's disease; and type-2 diabetes.

90 tions used in the treatment of patients with Parkinson's disease are associated with motor and non-mo

91 Progression markers of Parkinson's disease are crucial for successful therapeut

92 Stem cell-based therapies for Parkinson's disease are moving into a new and exciting e

93 ified, its roles in other disorders, such as Parkinson's disease, are starting to emerge, and A2AR an

94 nerative diseases, including Alzheimer's and Parkinson's disease, are thought to spread to increasing

95 tients were aged 25-75 years, had idiopathic Parkinson's disease as measured by Queen Square Brain Ba

96 i-site cohorts, and increased over 1 year in Parkinson's disease but not in controls at a single site

97 The latter is not constantly increased in Parkinson's disease, but comes in bursts of different du

98 nson's disease and individuals with sporadic Parkinson's disease, but LRRK2 mutation carriers without

99 tations are the most common genetic cause of Parkinson's disease, but LRRK2's normal physiological ro

100 s approach may enable clinical therapies for Parkinson's disease by delivery of genes rather than cel

101 esigned to generate a more faithful model of Parkinson's disease by injecting human alpha-syn fibril

102 Paper: Prying into the Prion Hypothesis for Parkinson's Disease, by Patrik Brundin and Ronald Melki.

103 standing of this step in the pathogenesis of Parkinson's disease can facilitate the development of di

104 People with Parkinson's disease can show premotor neurochemical chan

105 seases (i.e., Alzheimer's, Huntington's, and Parkinson's diseases), carcinogenesis, stroke, intracere

106 Parkinson's disease cases also increasingly reported anx

107 raging whole exome sequencing data from 1156 Parkinson's disease cases and 1679 control subjects.

108 In the past 5 years, Parkinson's disease cases developed additional motor fea

109 ears before diagnosis onwards, prediagnostic Parkinson's disease cases more commonly had problems in

110 e responsible for the majority of hereditary Parkinson's disease cases.

111 arkinson's patients selected from the Oxford Parkinson's Disease Centre Discovery Cohort and, after q

112 ompensatory processes.SIGNIFICANCE STATEMENT Parkinson's disease classically first becomes manifest i

113 55-85 years (about 2.2 million; dementia or Parkinson's disease cohort) who resided in Ontario, Cana

114 e posterior substantia nigra was elevated in Parkinson's disease compared to controls across single-

115 hway.SIGNIFICANCE STATEMENT Individuals with Parkinson's disease dementia often suffer a characterist

116 the treatment of synucleinopathies, such as Parkinson's disease, dementia with Lewy bodies, and mult

117 non-motor features in the 23 years preceding Parkinson's disease diagnosis by performing a nested cas

118 In patients with Parkinson's disease, elevations in beta activity (13-35

119 sing data from nine cohorts of patients with Parkinson's disease from North America and Europe assess

120 Neurotoxins associated with Parkinson's disease fully engages ER-p38 MAPK-CMA pathwa

121 BACKGROUND & AIMS: In most patients with Parkinson's disease, gastrointestinal (GI) dysfunctions,

122 ine LRRK2 mutation carriers without manifest Parkinson's disease had significantly elevated serotonin

123 Sporadic Parkinson's disease has been proposed to develop after i

124 Loss of dopaminergic (DA) neurons leads to Parkinson's disease; however, the mechanism(s) for the v

125 n free water in a subset of 46 patients with Parkinson's disease imaged at baseline, 12, 24, and 48 m

126 n conclusion, in patients with prediagnostic Parkinson's disease, impairments in instrumental daily a

127 eveloped clinically defined synucleinopathy (Parkinson's disease in 11, dementia with Lewy bodies in

128 might model aspects of the neuropathology of Parkinson's disease in mouse, we targeted RGMa to adult

129 h to study basal ganglia pathologies such as Parkinson's disease in silico.

130 ted approach to study BG pathologies such as Parkinson's disease in silico.

131 Here we describe an alternative strategy for Parkinson's disease in which dopamine neurons are genera

132 contribute to clinical differences in LRRK2 Parkinson's disease, including the emergence of non-moto

133 Neurotoxins that mimic Parkinson's disease increased Cav1.3 function, decreased

134 In Parkinson's disease, intracellular alpha-synuclein inclu

135 Deep brain stimulation (DBS) for Parkinson's disease is a highly effective treatment in c

136 Parkinson's disease is associated with an increased inci

137 gy-independent manner.SIGNIFICANCE STATEMENT Parkinson's disease is characterized by progressive moto

138 he future.Dual Perspectives Companion Paper: Parkinson's Disease Is Not Simply a Prion Disorder, by D

139 to be phosphorylated in the presence of the Parkinson's disease kinase PINK1 but the downstream sign

140 non-invasively alleviated symptoms in mouse Parkinson's disease models.

141 tablished and identified novel predictors of Parkinson's disease motor progression.

142 the most common neurosurgical treatment for Parkinson's disease motor symptoms.

143 elated diseases such as Alzheimer's disease, Parkinson's disease, multiple sclerosis and cardiovascul

144 LRRK2 mutation carriers with manifest Parkinson's disease (n=15) had reduced striatal dopamine

145 LRRK2 mutation carriers without manifest Parkinson's disease (n=25) had greater (18)F-FDOPA uptak

146 In a mouse model of Parkinson's disease, NeAL218 alone reprograms adult stri

147 th amounts seen in individuals with sporadic Parkinson's disease of similar duration.

148 shopping occur in about 17% of patients with Parkinson's disease on dopamine agonists.

149 No association was found with Parkinson's disease or multiple sclerosis.

150 a higher incidence of dementia, but not with Parkinson's disease or multiple sclerosis.

151 -9)), cognitive decline (P=5.3 x 10(-4)) and Parkinson's disease (P=8.6 x 10(-3)).

152 arkinson's disease, and people with sporadic Parkinson's disease, p<0.0001), striatum (compared with

153 d with LRRK2 mutation carriers with manifest Parkinson's disease, p=0.01), after adjustment for age.

154 striatum (compared with people with sporadic Parkinson's disease, p=0.02), and brainstem (compared wi

155 ce the importance of lysosomal mechanisms in Parkinson's disease pathogenesis.

156 ior of alpha-synuclein is a key component in Parkinson's disease pathogenesis.

157 nuclein (alpha-SYN) is a central molecule in Parkinson's disease pathogenesis.

158 Following genetic screening of Parkinson's disease patients and healthy controls, we al

159 Parkinson's disease patients demonstrated an altered pat

160 N) activity and electroencephalography in 11 Parkinson's disease patients during a perceptual decisio

161 corded from the subthalamic nucleus of eight Parkinson's disease patients during temporary lead exter

162 howed non-motor symptoms experienced by many Parkinson's disease patients including impaired cognitiv

163 Eighteen Parkinson's disease patients learned through feedback ON

164 from deep brain stimulation electrodes in 9 Parkinson's disease patients.

165 appearance of dyskinesia in the majority of Parkinson's disease patients.

166 ively correlated with clinical impairment in Parkinson's disease patients.

167 Studies suggest a greater risk of Parkinson's disease (PD) after traumatic brain injury (T

168 lphaS) forms round cytoplasmic inclusions in Parkinson's disease (PD) and dementia with Lewy bodies (

169 rative conditions (Alzheimer's disease (AD), Parkinson's disease (PD) and Huntington's disease (HD),

170 Neuroendocrine abnormalities are common in Parkinson's disease (PD) and include disruption of melat

171 alpha-syn) toxicity, a protein implicated in Parkinson's Disease (PD) and other neurodegenerative dis

172 (GBA) confer a heightened risk of developing Parkinson's disease (PD) and other synucleinopathies, re

173 ative disorders and is a hallmark feature of Parkinson's disease (PD) and PD-related diseases.

174 The motor symptoms of Parkinson's disease (PD) are linked to abnormally correl

175 ) is increasingly used in mid- to late-stage Parkinson's disease (PD) but with an incomplete knowledg

176 computational model for beta oscillations in Parkinson's disease (PD) can also account for complex pa

177 ohort of, at baseline, patients with de novo Parkinson's disease (PD) compared with healthy controls

178 re to PM air pollution is related to risk of Parkinson's disease (PD) in the Health Professionals Fol

179 Parkinson's disease (PD) is a chronic and progressive ne

180 Parkinson's disease (PD) is a circuit-level disorder wit

181 Parkinson's disease (PD) is a neurodegenerative disease

182 patients and carriers.SIGNIFICANCE STATEMENT Parkinson's disease (PD) is a prevalent neurodegenerativ

183 Parkinson's disease (PD) is associated with increased ir

184 Parkinson's disease (PD) is associated with the formatio

185 Parkinson's disease (PD) is characterized by a progressi

186 Parkinson's disease (PD) is characterized by slow, progr

187 Parkinson's disease (PD) is defined by the loss of dopam

188 Parkinson's disease (PD) is highly comorbid for a spectr

189 While the pathogenesis of Parkinson's disease (PD) is incompletely understood, mit

190 Parkinson's disease (PD) is one of the most common neuro

191 Parkinson's disease (PD) is the most common neurodegener

192 A major hallmark of Parkinson's disease (PD) is the presence of Lewy bodies

193 Individuals with Parkinson's disease (PD) often suffer from comorbid depr

194 a-Synuclein (alphaS) has a prominent role in Parkinson's disease (PD) pathology.

195 Parkinson's disease (PD) patients accumulate misfolded a

196 s of purified iPSC-derived DaNs derived from Parkinson's disease (PD) patients carrying LRRK2 G2019S

197 Parkinson's disease (PD) patients experience loss of nor

198 of cellular dysfunctions which may underlie Parkinson's disease (PD) progression.

199 Parkinson's Disease (PD) psychosis refers to the spectru

200 Using a transgenic mouse model of Parkinson's disease (PD) that expresses GFP-ASYN driven

201 paminergic (mDA) neurons from stem cells for Parkinson's Disease (PD) therapy; however, production of

202 Here, we tested the ability of patients with Parkinson's disease (PD) to maximize monetary rewards an

203 of 'awake' deep brain stimulation (DBS) for Parkinson's disease (PD) under local or general anaesthe

204 reductions of cerebral glucose metabolism in Parkinson's disease (PD) with 18F-fluorodeoxyglucose (FD

205 Retinal degeneration is prominent in Parkinson's disease (PD), a neuromotor disorder associat

206 PINK1 is mutated in Parkinson's disease (PD), and mutations cause mitochondr

207 lay a primary role in the pathophysiology of Parkinson's disease (PD), and small molecules that count

208 ght as a novel target for both addiction and Parkinson's disease (PD), as well as other emerging dise

209 PARK7 are a rare cause of familial recessive Parkinson's disease (PD), but growing evidence suggests

210 ntia nigra dopaminergic neurodegeneration in Parkinson's disease (PD), but how these pathways are lin

211 function and dementia are common features of Parkinson's disease (PD), causing significant disability

212 everal neurodegenerative diseases, including Parkinson's disease (PD), creating a critical need to id

213 disorders such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and

214 of toxic aggregates in neurons vulnerable in Parkinson's disease (PD), including dopaminergic neurons

215 To understand the cause of Parkinson's disease (PD), it is important to determine t

216 cated in neurodegenerative disorders such as Parkinson's disease (PD), it is important to examine how

217 del is the most widely used animal model for Parkinson's disease (PD), it is known that nigrostriatal

218 By applying PRISM to a yeast model of Parkinson's disease (PD), we identified guide RNAs (gRNA

219 phaSyn) is the major gene linked to sporadic Parkinson's disease (PD), whereas the G209A (p.A53T) alp

220 kinase 2 (LRRK2) and alpha-synuclein lead to Parkinson's disease (PD).

221 ve symptomatic therapy for motor deficits in Parkinson's disease (PD).

222 a (SN) to neurodegenerative stressors causes Parkinson's disease (PD).

223 oxicity are important etiological factors in Parkinson's disease (PD).

224 bute to the progression of neuropathology in Parkinson's disease (PD).

225 ful in identifying genes that cause familial Parkinson's disease (PD).

226 -synuclein as a possibly causative factor in Parkinson's disease (PD).

227 tions in LRRK2 are a common cause of genetic Parkinson's disease (PD).

228 ognitive impairment (MCI) is common in early Parkinson's disease (PD).

229 ociated with autosomal recessive early-onset Parkinson's disease (PD).

230 neurone disease) (sporadic and familial) and Parkinson's Disease (PD).

231 that contribute to falls among subjects with Parkinson's disease (PD).

232 compacta (SNpc) preferentially degenerate in Parkinson's disease (PD).

233 suggests that synapses are affected first in Parkinson's disease (PD).

234 ions is the defining pathological process in Parkinson's disease (PD).

235 have, to date, identified >24 risk loci for Parkinson's disease (PD).

236 or neurosurgical treatment of motor signs of Parkinson's disease (PD).

237 are the most common genetic risk factor for Parkinson's disease (PD).

238 ha-SYN) is a major pathologic contributor to Parkinson's disease (PD).

239 ssociated with increased risk for developing Parkinson's disease (PD).

240 in (alpha-syn) aggregation is a key event in Parkinson's disease (PD).

241 e of serotonergic pathology in patients with Parkinson's disease (PD).

242 ) is an emerging target for the treatment of Parkinson's disease (PD).

243 pars compacta (SNc) dopaminergic neurons in Parkinson's disease (PD).

244 reams and is a potential prodromal marker of Parkinson's disease (PD).

245 to the pathology of complex diseases such as Parkinson's Disease (PD).

246 ith an increased risk for the development of Parkinson's disease (PD).

247 ssociated with risk of familial and sporadic Parkinson's disease (PD).

248 itochondrial dysfunction and pathogenesis of Parkinson's disease (PD).

249 ted in monogenic recessive familial cases of Parkinson's disease (PD).

250 ), Creutzfeldt-Jakob disease (CJD, n = 239), Parkinson's disease (PD, n = 39), dementia with Lewy bod

251 2 mutation carriers with or without manifest Parkinson's disease, people with sporadic Parkinson's di

252 ions of Parkin cause some monogenic forms of Parkinson's disease, possibly through its role in mitoch

253 Parkinson's disease predisposing LRRK2 kinase phosphoryl

254 rexpression of mutant alpha-synuclein causes Parkinson's disease, presumably by driving neurodegenera

255 or cell type in the brain, yet their role in Parkinson's disease progression remains elusive.

256 ce in the Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) motor subsc

257 using the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part I scor

258 luding the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III, o

259 s from the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) parts II an

260 e were no significant differences in Unified Parkinson's Disease Rating Scale (UPDRS) Section II scor

261 Scale, and Movement Disorder Society Unified Parkinson's Disease Rating Scale motor scores; 0.76, 0.6

262 rior, and whole SNpc correlated with Unified Parkinson's Disease Rating Scale scores (r(2) = 0.25, 0.

263 analyses, and correlations with the Unified Parkinson's Disease Rating Scale scores were tested.

264 change in PD clinical scale scores (Unified Parkinson's Disease Rating Scale) and DAT imaging during

265 symptoms (Movement Disorder Society Unified Parkinson's Disease Rating Scale, MDS-UPDRS III), fitnes

266 390 patients with Parkinson's disease recruited between July 1, 2010, and

267 ses, we hypothesized that of the three major Parkinson's disease-related proteins-alpha-synuclein, LR

268 nvolved in amyotrophic lateral sclerosis and Parkinson's disease, respectively, using the small nine

269 e disorder gene variants in association with Parkinson's disease risk.

270 s well as neuropsychiatric disorders such as Parkinson's disease, schizophrenia, mood disorders, and

271 In Parkinson's disease, several studies have shown the feas

272 but LRRK2 mutation carriers without manifest Parkinson's disease show increased serotonin transporter

273 ine vs 7.33 [3.52] after dim-red LT) and the Parkinson's Disease Sleep Scale (97.24 [22.49] at baseli

274 e sex, and increased age, as well as a novel Parkinson's disease-specific epistatic interaction, all

275 milies with dominant inheritance patterns of Parkinson's disease, suggesting that it might confer a s

276 In patients with Parkinson's disease, the grafted tissue was characterize

277 INTERPRETATION: In newly diagnosed Parkinson's disease, the occurrence of cognitive impairm

278 ction mutations of PINK1 lead to early onset Parkinson's disease, there has been growing interest in

279 sorders and the neuropsychiatric symptoms of Parkinson's disease, these findings have clinical implic

280 ate with graft outcome in an animal model of Parkinson's disease through gene expression analysis of

281 lly relevant neuroendocrine abnormalities in Parkinson's disease to highlight their role in overall p

282 ere loss, as seen in Alzheimer's disease and Parkinson's disease, to relatively little loss, as seen

283 abetes mellitus, a-synuclein associated with Parkinson's disease, transthyretin V30M mutant associate

284 .05 gave good classification performance for Parkinson's disease tremor and essential tremor, in both

285 neurosurgery for movement disorders such as Parkinson's disease, tremor, and dystonia involves the p

286 of dopaminergic neurons in a mouse model of Parkinson's disease using 1-methyl-4-phenyl-1,2,3,6-tetr

287 ubjects and a group of elderly subjects with Parkinson's disease using an event-related functional MR

288 tivity on non-motor symptoms associated with Parkinson's disease using conditional knockout (cKO) mic

289 rt was followed-up for the onset of clinical Parkinson's disease using several overlapping modalities

290 ebo-controlled trial, patients with moderate Parkinson's disease were randomly assigned (1:1) to rece

291 nts suffering from dopamine depletion due to Parkinson's disease were selectively impaired in reward

292 gait and posture, phenotypes reminiscent of Parkinson's disease, were evident when the mutation was

293 egenerative diseases such as Alzheimer's and Parkinson's disease where optic nerve involvement has, u

294 ra is a valid, progression imaging marker of Parkinson's disease, which may be used in clinical trial

295 cally defined off-medication motor scores in Parkinson's disease, which were sustained beyond the per

296 so be seen in patients with Huntington's and Parkinson's disease who had received foetal neural allog

297 and striatal binding ratio in a subgroup of Parkinson's disease who had undergone both diffusion and

298 3200 patients with Parkinson's disease who were longitudinally assessed wit

299 enetic studies have shown the association of Parkinson's disease with alleles of the major histocompa

300 ese responses may explain the association of Parkinson's disease with specific major histocompatibili

301 r binding than did individuals with sporadic Parkinson's disease, with (18)F-FDOPA uptake comparable